KRAS Inhibitors Market Insight 2034: Revenue, Statistics, EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Therapies, Prevalence, Companies by DelveInsight

(Albany, USA) The report titled "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast- 2034" by DelveInsight provides a comprehensive analysis of KRAS Inhibitors. It presents a detailed overview of the historical and projected epidemiological data, along with the market trends for KRAS Inhibitors in the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The report on the KRAS Inhibitors market offers up-to-date treatment methods, upcoming medications, the market share of different therapies, and the present as well as projected size of the KRAS Inhibitors market from 2020 to 2034. The market is divided into seven major segments. Additionally, the report examines the existing treatment practices and strategies for KRAS Inhibitors, factors driving market growth, obstacles encountered, and medical needs that have yet to be addressed. This comprehensive assessment aims to identify the most promising opportunities and evaluate the inherent potential of the KRAS Inhibitors market.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the KRAS Inhibitors Market Report are:
• According to DelveInsight, KRAS Inhibitors market size is expected to grow at a decent CAGR by 2034.
• Leading KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
• Promising KRAS Inhibitors Therapies expected to launch in the market are LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), JDQ443, Divarasib, and others.
• On May 8, 2025, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
• In April 2025, Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation. The Company expects to initiate a Phase 1/2a study in mid-2025 with plans for multiple expansion cohorts, including combinations, in advanced solid tumors, such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
• In January 2025, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company at the forefront of developing innovative oral therapies for RAS-driven cancers, announced advancements in its pipeline of KRAS-directed drug candidates. This includes the clearance of a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application for QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor, which allows the initiation of a Phase 1 clinical trial.
• In June 2024, Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing innovative oral treatments for RAS-driven cancers, announced the progress of two clinical trials from its pipeline of KRAS-directed drug candidates. The first patient has been dosed in the monotherapy phase of a Phase 1 trial evaluating QTX3046, a KRASG12D-selective inhibitor. Additionally, patient dosing has commenced in the combination phase of the ongoing Phase 1 trial assessing QTX3034, a multi-KRAS inhibitor that preferentially targets G12D, in combination with cetuximab. Both trials are enrolling patients with KRASG12D-mutated advanced solid tumors.
• In February 2024, Bristol Myers Squibb reported that the US FDA has granted priority review status to the supplemental New Drug Application (sNDA) for KRAZATI in combination with cetuximab for the treatment of KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024.
• In April 2023, BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen's LUMAKRAS® (sotorasib)
• In May 2023, Mirati Therapeutics announced Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients.
• In Jan 2023, Pfizer and Array BioPharma announced the Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

KRAS Inhibitors Overview
KRAS inhibitors are a specific form of targeted therapy devised to hinder the function of the KRAS gene, which plays a vital role in numerous types of cancer. The KRAS gene is part of a gene family called RAS genes and is responsible for regulating cellular division and growth. Mutations in the KRAS gene can prompt uncontrolled cell growth and division, ultimately leading to the formation of cancer.

Traditionally, it has been challenging to address KRAS mutations using conventional treatments, making KRAS-driven cancers particularly difficult to manage. However, considerable advancements have been made in recent years with the development of KRAS inhibitors that effectively impede the abnormal activity of mutated KRAS proteins. These inhibitors are specifically designed to target the altered KRAS protein, aiming to disrupt its signalling pathways and hinder the growth of cancerous cells.

Learn more about KRAS Inhibitors treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

KRAS Inhibitors Market

The KRAS Inhibitors market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted KRAS Inhibitors market trends by analyzing the impact of current KRAS Inhibitors therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the KRAS Inhibitors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated KRAS Inhibitors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the KRAS Inhibitors market in 7MM is expected to witness a major change in the study period 2020-2034.

KRAS Inhibitors Epidemiology

The KRAS Inhibitors epidemiology section provides insights into the historical and current KRAS Inhibitors patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the KRAS Inhibitors market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about KRAS Inhibitors Epidemiology @ https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

KRAS Inhibitors Drugs Uptake

The KRAS Inhibitors Drugs Uptake section emphasizes the rate at which the newly introduced KRAS Inhibitors medications in the market, or those projected to be launched between 2020 and 2034, are being adopted. The examination encompasses the adoption of drugs in the KRAS Inhibitors market, the acceptance of therapies by patients, and the sales figures for each medication.

KRAS Inhibitors Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on KRAS Inhibitors market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

KRAS Inhibitors Pipeline Development Activities

The KRAS Inhibitors report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses KRAS Inhibitors key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the KRAS Inhibitors pipeline development activities @ https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

KRAS Inhibitors Therapeutics Assessment

Major key companies are working proactively in the KRAS Inhibitors Therapeutics market to develop novel therapies which will drive the KRAS Inhibitors treatment markets in the upcoming years are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.

Learn more about the emerging KRAS Inhibitors therapies & key companies @ https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

KRAS Inhibitors Report Key Insights

1. KRAS Inhibitors Patient Population
2. KRAS Inhibitors Market Size and Trends
3. Key Cross Competition in the KRAS Inhibitors Market
4. KRAS Inhibitors Market Dynamics (Key Drivers and Barriers)
5. KRAS Inhibitors Market Opportunities
6. KRAS Inhibitors Therapeutic Approaches
7. KRAS Inhibitors Pipeline Analysis
8. KRAS Inhibitors Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the KRAS Inhibitors Market

Table of Contents

1. Key Insights
2. Executive Summary
3. KRAS Inhibitors Competitive Intelligence Analysis
4. KRAS Inhibitors Market Overview at a Glance
5. KRAS Inhibitors Disease Background and Overview
6. KRAS Inhibitors Patient Journey
7. KRAS Inhibitors Epidemiology and Patient Population
8. KRAS Inhibitors Treatment Algorithm, Current Treatment, and Medical Practices
9. KRAS Inhibitors Unmet Needs
10. Key Endpoints of KRAS Inhibitors Treatment
11. KRAS Inhibitors Marketed Products
12. KRAS Inhibitors Emerging Therapies
13. KRAS Inhibitors Seven Major Market Analysis
14. Attribute Analysis
15. KRAS Inhibitors Market Outlook (7 major markets)
16. KRAS Inhibitors Access and Reimbursement Overview
17. KOL Views on the KRAS Inhibitors Market
18. KRAS Inhibitors Market Drivers
19. KRAS Inhibitors Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the KRAS Inhibitors Market report here @ https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/ats-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.